EFPIA and PhRMA Accused of Mobilising Patients Against EU Trial Transparency Plans

By Dan Stanton

- Last updated on GMT

EFPIA and PhRMA Accused of Mobilising Patients Against EU Trial Publishing Plans
EFPIA and PhRMA Accused of Mobilising Patients Against EU Trial Publishing Plans

Related tags Clinical trial Big pharma Pharmaceutical industry

The EFPIA and PhRMA are targeting an "army" of patient groups to lobby EU plans to publish clinical trial data, according to a leaked memo.

In May, clinical trial data transparency moved towards becoming a reality when the European Parliament’s Committee on Environment and Public Health (ENVI) voted to adopt draft rules to Clinical Trials Regulations.

However, in an email leaked to the The Guardian​, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has called upon Big Pharma to mobilise "patient groups to express concern about the risk to public health by non-scientific re-use of data,”​ as part of an attack on the new legislation.

The Pharmaceutical Research and Manufacturers of America (PhRMA) – cited by the British newspaper as drawing up the strategy with the EFPIA – sent in-Pharmatechnologist.com a statement saying the “EMA's proposed policies on clinical trial information raise numerous concerns for patients.

“We believe it is important to engage with all stakeholders in the clinical trial ecosystem, including the patients who volunteer to participate in clinical trials, about the issue.”

The transparency amendment was unanimously voted in by the European Parliament will and is expected to come into force in 2016. The office of Glenis Willmott MEP, who steered the legislation, told in-Pharmatechnologist.com in May“transparency requirements are proportionate and achievable and clearly in the public interest.”

The EFPIA did not respond to requests for comment.

Patient Group and Big Pharma Respond

The allegation that Big Pharma is trying to patient groups to combat the proposed legislation was denounced by the European Patients Forum (EPF), an umbrella organisation that works with patients’ groups across Europe.

In a statement sent to this publication, the group said it “consistently called for the publication of all results of all clinical trials, be they industry or publicly funded, in a timely manner, regardless of the outcomes,”​ as reflected in its support of transparency advocates Alltrials.net.

Furthermore, the EPF said they were “not aware of any bona fide patient group that would advocate another stance” ​and questioned who the "army"​ of patients ready to mobilise on behalf of Big Pharma referred to in the Guardian actually are.

Pharma companies too targeted by the memo - including Roche, GSK and Eli Lilly - told the Guardian they had not been involved in the EFPIA’s plan to target patient groups.

Furthermore, GSK has been actively supporting clinical trial transparency in its own data, stepping away from the industry groups’ attempts to halt legislation. Last year the company announced​ it intended to publish all its clinical study reports since 2000, aligning itself with Alltrials.net and the British Medical Journal.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines